Tarsus to Participate in Upcoming Investor Conference

Tarsus (NASDAQ:TARS) said management will participate in a fireside chat at BTIG 5th Annual Ophthalmology Day on Monday, December 1, 2025 at 10:45 a.m. PT / 1:45 p.m. ET.

Rhea-AI Summary

Tarsus (NASDAQ:TARS) said management will participate in a fireside chat at BTIG 5th Annual Ophthalmology Day on Monday, December 1, 2025 at 10:45 a.m. PT / 1:45 p.m. ET.

A live webcast will be available on the events section of the Tarsus website, and a replay will be posted within 48 hours and archived for a limited time.

Argus Nov 25 session

-3.93% close to close Open Argus

Details

News Market Reaction – TARS

On Nov 25, the first trading day after this news, TARS closed 3.93% below the previous close.

Data tracked by StockTitan Argus for the Nov 25 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5^th Annual Ophthalmology Day on Monday, December 1^st, at 10:45 a.m. PT / 1:45 p.m. ET.

A live webcast and additional information can be accessed on the events section of the Tarsus website. The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea, and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Tarsus (TARS) present at BTIG Ophthalmology Day?

Tarsus management will present on December 1, 2025 at 10:45 a.m. PT / 1:45 p.m. ET.

How can investors watch the Tarsus (TARS) fireside chat on December 1, 2025?

Investors can view the live webcast on the events section of the Tarsus website.

Will a replay of the Tarsus (TARS) BTIG presentation be available after the event?

Yes. A replay will be posted on the Tarsus website within 48 hours and archived for a limited time.

What topics will Tarsus (TARS) cover in the BTIG fireside chat?

The announcement states management will participate in a fireside chat; specific topics were not listed.

Where on the Tarsus website is the live webcast and replay for the BTIG event located?

The webcast and replay are available in the events section of the Tarsus website.

Is the Tarsus (TARS) BTIG presentation scheduled during market hours on December 1, 2025?

The presentation is scheduled at 10:45 a.m. PT / 1:45 p.m. ET, which falls during U.S. market hours.